Mette Thune Mouritzen
4PUBLICATIONS
17CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Sep 28, 2023
Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.Mette T Mouritzen, Morten Ladekarl, Henrik Hager
|Aug 03, 2023
5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.Birgitte Bjørnhart, Mette Thune Mouritzen, Charlotte Kristiansen
|Jan 11, 2022
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.Mette T Mouritzen, Karen F Junker, Andreas Carus
|Oct 13, 2021
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy.Mette T Mouritzen, Andreas Carus, Morten Ladekarl
Pageof 1
Frequent Collaborators
3 joint publications
Morten Ladekarl
3 joint publications
Charlotte Kristiansen
3 joint publications
Birgitte Bjørnhart
2 joint publications
Andreas Carus
2 joint publications
Jacob W Larsen
2 joint publications
Jens B Sørensen
2 joint publications
Seppo W Langer
1 joint publications
Anna Livbjerg
1 joint publications
Anne-Cathrine Østby
1 joint publications
Charles Vesteghem
